Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enbrel Sales Near Production Cap; New Plant To Produce Clinical Lots In 2001

Executive Summary

Immunex will use its newly acquired Rhode Island production facility to supply Enbrel (etanercept) for clinical trials during 2001.

You may also be interested in...



Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List

Rheumatoid arthritis patients wishing to start Wyeth/Immunex' Enbrel after Dec. 31 will be placed on a waiting list under the Enbrel Enrollment program.

Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List

Rheumatoid arthritis patients wishing to start Wyeth/Immunex' Enbrel after Dec. 31 will be placed on a waiting list under the Enbrel Enrollment program.

Caremark Forecasts 25%-30% Mail Service Growth For 2001

Caremark expects its mail order prescription volume to increase by 25%-30% during 2001, the company told a Nov. 1 earnings conference call.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel